The NIH Needs Reform: Here are 10 Sensible Suggestions
It is my pleasure to introduce this article by Joseph Marine, MD.
Related Articles
What if your ‘physician’ wasn’t actually a doctor at all? Beware this new reckless experiment | Rachel Clarke
The NHS says it’s not trying to replace qualified doctors with physician associates. But we can see the terrifying truth, says the palliative care doctor…
Public health staff told their jobs are on the line, on same day whooping cough epidemic announced
A “reset” to cut millions of dollars from the National Public Health Service will go ahead before Christmas, staff have been told.
Sickle Cell Trait, Inequity, and the Need for Change | NEJM
Because of misperceptions about risks, people with sickle cell trait in the United States may receive inequitable and potentially harmful treatment, with implications for autonomy,…
Are you serious? Thirteen questions for Boards to ask about NHS race equality data in your organisation.
I have recent examined a range of data on race equality presented to the Boards of Trusts and ICS Boards. In many cases the data…
Reach-the-World Fellowships – International Society on Thrombosis and Haemostasis, Inc.
This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our…
‘It’s impossible to breathe’: Life in the world’s most polluted city
Inside Delhi’s first ever clinic dedicated to pollution-related illnesses, Deepak Rajak struggles to catch his breath.
Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia
Abstract. Incorporation of the B-cell lymphoma 2 inhibitor venetoclax into the treatment of acute myeloid leukemia (AML) has been transformative. Initially studied in combination with…
The NIH Needs Reform: Here are 10 Sensible Suggestions
It is my pleasure to introduce this article by Joseph Marine, MD.
“Nailing down” risk and improving outcomes in early-stage breast cancer
Whether via the strain of academic advancement or hyper-competitive industry-funded drug-development landscape,1 there has been increasing focus to shift c
